Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 14/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946278 | 0.89 | PNP (0.58) | PNP | |
| SCHEMBL1946429 | 0.85 | PNP (0.67) | PNP | |
| SCHEMBL1947392 | 0.81 | PNP (1.00) | PNP | |
| SCHEMBL1947135 | 0.81 | PNP (0.61) | PNP | |
| SCHEMBL1945910 | 0.78 | PNP (0.71) | PNP | |
| SCHEMBL1947894 | 0.78 | PNP (0.71) | PNP | |
| SCHEMBL1945907 | 0.78 | PNP (0.71) | PNP | |
| SCHEMBL1415428 | 0.78 | PNP (0.64) | PNP | |
| SCHEMBL1948683 | 0.74 | PNP (0.62) | PNP | |
| SCHEMBL1946166 | 0.73 | PNP (0.70) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853224-B2 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2014-10-07 | — | — | US | claimed |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | BIOCRYST PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | claimed |
| US-10918641-B2 | Use of MTAP inhibitors for the treatment of lung disease | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180353511-A1 | Use of MTAP Inhibitors for the Treatment of Lung Disease | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2018-12-13 | — | — | US | disclosed |
| WO-2017062421-A1 | USE OF MTAP INHIBITORS FOR THE TREATMENT OF LUNG DISEASE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-04-13 | — | — | WO | disclosed |
| US-8853224-B2 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2014-10-07 | — | — | US | disclosed |
| EP-2395005-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | Industrial Research Limited (NZ) | 2011-12-14 | — | — | EP | disclosed |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | BIOCRYST PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353511-A1 | Use of MTAP Inhibitors for the Treatment of Lung Disease | MTAP, TYMP, TPMT | PNP 5/4885 |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | PNP, TYMP, NTPCR | PNP 1/4885 |
| US-10918641-B2 | Use of MTAP inhibitors for the treatment of lung disease | MTAP, TYMP, TPMT | PNP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.